Inclusion Criteria:

          -  Cytologically or histologically confirmed advanced solid tumor

          -  Radiographic progression on prior systemic therapy; prior localized therapy (i.e.,
             radiation, ablation, embolization) is allowed provided radiographic progression
             out-of-field or in the treatment, field is shown

          -  Locally-advanced (unresectable) or metastatic disease harboring an FGFR1-3 gene
             fusion/rearrangement potentially leading to a functional FGFR aberrant protein,
             identified through local and/or central molecular assay

        Exclusion Criteria:

          -  History of hypersensitivity to any of the excipients in the Debio 1347 formulation

          -  History and/or current evidence of ectopic mineralization/calcification, including but
             not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting
             calcified lymph nodes, lung nodules and asymptomatic vascular or cartilage/tendon
             calcifications

          -  Administration of any investigational agent within 2 weeks prior to initial dosing
             with Debio 1347 (3 weeks for immune checkpoint inhibitors)